Investee Company Update: Little Green Pharma Ltd

Seed Innovations Limited

07 September 2023

 

7 September 2023 

SEED Innovations Limited

("SEED" or the "Company")

Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM-quoted company investment company providing shareholders with exposure to early-stage health, wellness and medical cannabis companies to which, in normal circumstances, they have limited access to, is pleased to note an announcement released on the ASX by its portfolio company, Little Green Pharma Ltd ('LGP').

The Company owns 7,324,796 ordinary shares in LGP representing 2.44% of LGP's issued share capital.

The following announcement, which was released on the ASX is set out without any material changes.

Large Scale Cannabis Study Findings Released

Results find medicinal cannabis significantly improves pain, quality of life & fatigue.

Little Green Pharma (ASX: LGP) wishes to advise of a media release issued today relating to the analysis of the initial three month results from the QUEST Initiative[1] . A copy of that media release is appended to this link: https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf 

Analysis of the initial three-month follow-up results from 2,327 Australian patients participating in the QUEST Initiative show:

·    very strong evidence of clinically meaningful improvements for those suffering health-related quality of life (HRQL) and fatigue

·    clinically meaningful reductions in pain and significant improvements for moderate-severe anxiety and depression

Analysis of 12-month results is currently being undertaken to see if such improvements are maintained over the longer term.

Overview

The QUEST Initiative, sponsored by LGP, was one of the world's largest longitudinal clinical studies investigating the effect of medicinal cannabis on patient quality of life and health economic impacts. The study was led by a leading Australian university with LGP exclusively supplying the medicinal cannabis products to patients enrolled in the study and with Study costs fully funded from patient participation fees. The study was also supported by not-for-profit private health insurance provider Health Insurance Fund of Australia (HIF) and guided by an experienced advisory group and endorsed by a range of national bodies, such as MS research Australia, Chronic Pain Australia, Arthritis Australia and Epilepsy Australia. For a full analysis of the results, please refer to the link attached.

The announcement in full can be accessed from the following link: https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf

- Ends -

For further information on the Company please visit:    www.seedinnovations.co     or contact: 

Ed McDermott  Lance de Jersey	SEED Innovations Ltd	E: [e-mail]
James Biddle  Roland Cornish	Beaumont Cornish Limited,  Nomad	T: (0)20 7628 3396
Isabella Pierre  Damon Heath	Shard Capital Partners LLP  Broker	T: (0)20 7186 9927
Catherine Leftley  Ana Ribeiro Isabelle Morris	St Brides Partners Ltd,  Financial PR	E: [e-mail]

Notes 

Seed Innovations Ltd 

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each. 

About Little Green Pharma 

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. 

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m2 cultivation and 4,000m2 GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum. 

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. 

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems. 

---

[1] Refer to ASX announcement dated 18 February 2021.

 

END